肝细胞肝癌患者血清可溶性Fas检测及临床意义

目的检测肝细胞肝癌患者血清可溶性Fas（sFas）水平,探讨其在肝癌发生机制中的作用。方法用酶联免疫吸附法（ELISA）检测了31例肝细胞肝癌患者和20例健康人血清sFas水平,并与其它实验指标做相关性比较。结果肝细胞肝癌患者血清sFas水平（5.9±2.0）ng/ml明显高于正常对照组（2.6±0.8）ng/ml（t=3.87,P〈0.01）;患者血清sFas与肝炎活动程度指标无相关性。结论外周血中sFas水平异常可能在肝细胞肝癌的发生发展中起重要作用。

Detection of Serum Soluble Fas and it's Clinical Significance in Patiens with Hepatocellular Carcinoma

Objective To investigate the detection of serum soluble Fas（sFas） and its significance of pathogenesis of hepatocellular carcinoma. Methods Serum sFas was detected in 31 patients with hepatocellular carcinoma and 20 normal controls by ELISA. Results The patients with hepatoeellular carcinoma showed higher levels of serum sFas （5.9 ± 2.0） ng/ml than controls （2.6 ± 0.8） ng/ml （ t = 3.87,P 〈 0.01 ）. Serum sFas level was not related to activity parameters of hepatitis disease in patiens with hepatoeellular carcinoma. Conclusions Increased serum sFas might play an important role in the development of hepatocellular carcinoma.